Healthcare stocks were falling premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) down 0.6%.
Arrowhead Pharmaceuticals' (ARWR) plozasiran met its primary and secondary endpoints in two phase 3 studies as a potential treatment for adults with severe hypertriglyceridemia, the company said. Shares of Arrowhead Pharmaceuticals were down more than 2% pre-bell.
Hutchmed (HCM) shares were up more than 2% after the company said its experimental combination of Orpathys and Tagrisso demonstrated a statistically significant improvement in progression-free survival in a China phase 3 trial involving certain patients with non-small cell lung cancer.
IDEAYA Biosciences (IDYA) stock was 0.7% higher after the company said it held a US Food and Drug Administration meeting on the design of a phase 3 trial for IDE849, its experimental treatment for extensive-stage small cell lung cancer.